Biotech Values

[DewDiligence]

>The [NM283] deal was over the top imo, huge payments to the private shareholders and huge bonus money to those private shareholders if the hcv drug work out (I don't recall if they get bonus money for the hbv drug).<

The third-party earn-out pertains to only NM283, not to Telbivudine.

>That [NM283] deal was several years ago as well.<

Indeed. This is part of the reason I think VRTX could have done better on the VX-950 deal. Not only is 950 much the better drug, but the 950 deal was struck at a later stage in development than the NM283 deal.